Kodiak Sciences Inc.
KOD
Rang in Aktien
#3149
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical... Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Aktienkurs
$91.35
Zuletzt synchronisiert: 2026-10-19
Marktkapitalisierung
$5.74B
Veränderung (1 Tag)
6.53%
Veränderung (1 Jahr)
416.10%
Land
US
Handel Kodiak Sciences Inc. (KOD)
Kategorie
Healthcare
Aktien-Split-Historie für Kodiak Sciences Inc. (KOD)
Die Aktie Kodiak Sciences Inc. (Symbol: KOD) durchlief insgesamt 1 Aktiensplits.
Der letzte Aktiensplit fand am Feb 23, 2022 statt.
Eine KOD-Aktie, die vor dem Feb 23, 2022 gekauft wurde, entspricht heute 5 KOD-Aktien.
Der letzte Aktiensplit fand am Feb 23, 2022 statt.
Eine KOD-Aktie, die vor dem Feb 23, 2022 gekauft wurde, entspricht heute 5 KOD-Aktien.
Liste der Aktiensplits
| Jahr | Aktien-Split | Multiplikator | Kumulierter Multiplikator |
|---|---|---|---|
| 2022-02-23 | 5:1 | x5 | x5 |
Aktiensplits ähnlicher Unternehmen oder Wettbewerber
| Unternehmen | Anzahl der Aktiensplits | Kumulierter Multiplikator | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
